Experimental antibody takes aim at tough lymphoma
NCT ID NCT02520791
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing an experimental antibody called MEDI-570 in 21 people with certain types of T-cell lymphoma that have come back or not responded to treatment. The goal is to find the safest dose and see how the body handles the drug. MEDI-570 works by targeting a protein on immune cells to potentially slow cancer growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MEDI-570 (an antibody that targets a protein on immune cells to help fight cancer)
- What this could lead to
- If successful, this could point toward a new treatment option for certain hard-to-treat T-cell lymphomas.
- What could go wrong
- This is a very early phase 1 trial with only 21 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
BCCA-Vancouver Cancer Centre
Vancouver, British Columbia, V5Z 4E6, Canada
-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Houston, Texas, 77030, United States
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Montefiore Medical Center - Moses Campus
The Bronx, New York, 10467, United States
-
Montefiore Medical Center-Einstein Campus
The Bronx, New York, 10461, United States
-
Montefiore Medical Center-Weiler Hospital
The Bronx, New York, 10461, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri, 63141, United States
-
Siteman Cancer Center-South County
St Louis, Missouri, 63129, United States
-
Smilow Cancer Center/Yale-New Haven Hospital
New Haven, Connecticut, 06510, United States
-
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, 75390, United States
-
University Health Network-Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
-
University of Kansas Clinical Research Center
Fairway, Kansas, 66205, United States
-
University of Kentucky/Markey Cancer Center
Lexington, Kentucky, 40536, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Yale University
New Haven, Connecticut, 06520, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug duo outsmart resistant T-Cell lymphoma?
- New drug cocktails aim to outsmart Hard-to-Treat T-Cell lymphomas
- Immunotherapy combo shows promise for Tough-to-Treat blood cancers
- New drug cocktail aims to tackle rare blood cancer
- New combo shows promise for rare blood cancer
- Engineered immune cells target lymphoma after transplant